Compare InMode Ltd (INMD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Merck & Co., Inc. — how do they compare? InMode Ltd trades at $15.24 (market cap $872.08M), while Merck & Co., Inc. trades at $133.62 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 369× InMode Ltd's market cap, and Merck & Co., Inc. pays a 2.61% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| INMD | MRK | |
|---|---|---|
Market Cap | $872.08M | $321.77B |
Sector | Technology | Health |
52-Week High | $16.62 | $131.84 |
52-Week Low | $12.76 | $77.60 |
Enterprise Value | $375.42M | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.24, up 0.33% on the day, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company maintains strong profitability with a 20.69% net income margin and attractive valuation ratios, including a P/E of 12.52. Recent news highlights include Q2 2026 results consistent with the prior year and an unsolicited acquisition proposal from Steel Partners at $16.75 per share.
The stock presents a value opportunity given its low valuation multiples and high margins, but faces near-term uncertainty from shareholder activism, a securities fraud investigation, and potential acquisition volatility. Analyst sentiment is divided between Buy and Hold ratings, reflecting the balance between fundamental strength and corporate governance concerns.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
